Groowe Groowe BETA

US Stock Market News

Stay on top of the US stock market with real-time breaking news and market-moving stories. Our platform continuously aggregates updates from trusted financial news sources, giving traders and investors a fast overview of events that may impact stock prices.

Whether you're tracking specific companies or scanning the broader market, the news feed helps you quickly identify important developments as they happen.

Create an account to access the live news feed. Access is free while the platform is in beta. Visitors without an account can still browse the latest headlines with a 15-minute delay.

⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

accessnewswire.com
ENGN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sleep Number Corporation - SNBR

accessnewswire.com
SNBR

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of B&G Foods, Inc. - BGS

accessnewswire.com
BGS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Armstrong World Industries, Inc. - AWI

accessnewswire.com
AWI

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Shake Shack, Inc. - SHAK

accessnewswire.com
SHAK

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forward Air Corporation - FWRD

accessnewswire.com
FWRD

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Angi Inc. - ANGI

accessnewswire.com
ANGI

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

accessnewswire.com
BIIB

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCS

accessnewswire.com
DOCS

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX ® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

businesswire.com
EXEL
View all news →